- Anticonvulsant Drugs
- Anti-anxiety Drugs
- Anti-coagulant Drugs
- Analgesics Drugs
- Anti-psychotic Drugs
- Anti-depressant Drugs
- Others
Traumatic Brain Injury Therapeutics Market size was valued at USD 3.2 billion in 2022 and is poised to grow at a CAGR of 7.9% from 2023-2029. The biggest opportunity provided by this market is there are only a few approved therapeutics products that have therapeutics potential and market value. The reason behind this is most medications cannot overcome the blood-brain barrier while delivering drugs hence it opens up the markets for numerous numbers of opportunities. NeuroSTAT is an appropriate example. This opens up opportunities for the key players to participate equally in treating highly vulnerable injury which doesn't have self-repair capability. 1.7 million people tend to have a sustained injury every year causing death and permanent disability. Hence to overcome all this global traumatic brain injury therapeutics market has to grow simultaneously.
This report studies global traumatic brain injury therapeutic market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global traumatic brain injury therapeutic market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global traumatic brain injury therapeutics market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
It is noticed that the global traumatic brain injury therapeutics market is influenced mainly by the number of road accidents are the key factor which is causing traumatic brain injury which ranges from Sustained, Severe and mild. 2030 Agenda for Sustainable Development has set an ambitious target of halving the global number of deaths and injuries from road traffic crashes by 2020. It is considered to the highly vulnerable injury, according to WHO 52,000 people die from road accident. The main important factors contributing to this event is low societal awareness, delayed diagnosis and very poor government funding. There are only a few therapy sections introduced for the global traumatic brain injury therapeutics market which include nanotech therapy, stem cell therapy, apoE-mimetic compounds. Finally, the global traumatic brain injury therapeutics market has to grow in order to reduce the number of people who are dying from accident because of the unavailability of proper medication and treatment procedure.
The traumatic brain injury therapeutics market size was valued at USD 3.2 billion in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
SFC Fluidics LLC, Banayan Biomarkers Inc., BHR Pharma LLC, Cerora Inc., ElMindA Ltd., Grace Laboratories LLC, KeyNeurotek Pharmaceuticals AG